FDA Reassigns Longtime Over the Counter Drugs Director, Sparks Concern

The Food and Drug Administration reassigned Theresa Michele, the agency’s longtime head of the Office of Nonprescription Drugs, to a leadership position in the medical devices center on December 3, 2025. Michele had overseen regulation of over the counter medicines since 2015, guiding policy on safety, labeling, and market authorizations for widely used therapies such as pain relievers, allergy medications, and cold and flu treatments.

Agency officials described the move as part of a broader management reorganization following the announced retirement of Richard Pazdur, the FDA’s drug evaluation chief, and as aligned with priorities set by Health Secretary Robert F. Kennedy Jr. Officials said Michele’s prior office will be reshaped with a greater emphasis on affordability, a policy aim that could shift how the agency evaluates product pathways and regulatory decisions.

The reassignment and the surrounding leadership turnover have generated concern among industry observers and public health stakeholders about upheaval and uncertainty at the FDA. Regulatory continuity and institutional expertise are central to the timely review of monograph changes, generic product entries, and safety communications that affect consumers, particularly older adults and low income communities that depend on affordable over the counter options.

Public health experts say any disruption within the office that regulates nonprescription medicines could have downstream effects on access and equity. Over the counter medications serve as front line care for common ailments, and interruptions to approval processes or delays in updated safety labeling can disproportionately affect people with limited access to clinical care. A renewed focus on affordability could deliver meaningful benefits if it results in lower prices or expanded access, but stakeholders caution that implementing cost oriented priorities without preserving scientific rigor and procedural stability risks unintended consequences.

Pharmacies, community clinics, and public health programs are watching how the reshaped office will balance affordability objectives with established evaluation standards. Manufacturers and trade groups have expressed unease that rapid personnel changes could slow regulatory decisions or create ambiguity about submission expectations. That uncertainty can affect supply chains and pricing negotiations, influencing what is available on neighborhood shelves and what insurance plans and public programs will cover or recommend.

For communities that rely on low cost self care, the stakes are practical and immediate. Policy shifts intended to make medicines more affordable must be matched with clear regulatory pathways and consistent leadership to avoid delays in approvals and keep the market functioning. As the agency implements the reassignment and new priorities, advocates and health providers plan to press for transparency about timelines and criteria so that decisions support both safety and equitable access.

The reassignment underscores the broader pressures facing a regulatory agency undergoing leadership change. Observers say the coming months will reveal whether the FDA can advance affordability goals while maintaining the steady, expert oversight that has governed nonprescription drug regulation for a decade.